Abstract 116P
Background
RAS mutation has become an important part of assessment of patients with colorectal cancer (CRC), but its role in colorectal cancer patients with initially unresectable liver metastases has yet to be elaborated. We aim to assess the role of RAS mutation on convertion of patients with initially unresectable colorectal liver metastases (CLMs).
Methods
We identified CRC patients who initially with unresectable liver metastases during January 2012 to December 2017 in Zhongshan Hospital Fudan University. The association between RAS status of primary tumor and characteristics of patients were analyzed. Conversion rates was determined.
Results
A total of consecutive 433 CLM patients with available RAS status were evaluated in this study, KRAS mutation rates was 41.5%, BRAF was 6.7% and NRAS was 1.6%. 258 patients were RAS wild type and 185 patients were mutant. RAS mutation were associated with right colon cancer (P = 0.006) and lymph node metastasis (P = 0.017). Among RAS wild type patients, 56.2% (145/258) received Cetuximab plus chemotherapy treatment, 7.8% (20/258) received Bevacizumab plus chemotherapy and the others received chemotherapy only. Among RAS mutant patients, 50.8% (94/185) received Bevacizumab plus chemotherapy and 49.2% (91/185) received chemotherapy only. RAS wild type patients had a better objective response rate (52.3% vs 37.3%, p = 0.011) and higher conversion rate (24.0% vs 12.4%, P = 0.002) compare with RAS mutant patients. For RAS wild type group, patients with Cetuximab plus chemotherapy, Bevacizumab plus chemotherapy and chemotherapy only have a conversion resection rate of 31.5% ,20% and 14.3% respectively P = 0.05 for RAS mutation group, Bevacizumab plus chemotherapy had a similar conversion resection rate compared with chemotherapy only (12.6% VS 11.3%, P = 0.815).
Conclusions
RAS wild type indicated a better conversion rate for patients with initially unresectable colorectal liver metastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract